



Product Information

Product Name	WA23
Lot Number	WB0101
Parent Material	WA23-WB0069
Depositor	WiCell
Banked by	WiCell
Thaw Recommendation	Thaw 1 vial into 1 well of a 6 well plate.
Culture Platform	Feeder Free
	Medium: Conditioned Medium
	Matrix: Matrigel
Protocol	WiCell Feeder Free Protocol
Passage Number	p18 These cells were cultured for 17 passages prior to freeze. WiCell adds +1 to the passage number at freeze so that the number on the vial best represents the overall passage number of the cells at thaw.
Date Viald	13-September-2011
Vial Label	WB0101 WA23 P18 NG 13SEPT2011
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.

Lot Specific Testing Performed by WiCell

The following tests were performed on this specific lot.

Test Description	Test Provider	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	≥ 15 Undifferentiated Colonies, ≤ 30% Differentiation	Pass
Identity by STR	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega	Consistent with known profile	Pass
Sterility - Direct transfer method	Apptec	30744	Negative	Pass
Mycoplasma	Bionique	M250	No contamination detected	Pass
Karyotype by G-banding	WiCell	SOP-CH-003	Normal karyotype	Pass

This cell line, but not this particular lot of material, was also tested for human viruses via Charles River's Comprehensive Human Virus Panel.



Product Information and Testing - Amended

General Cell Line Testing Performed by WiCell

The following tests were performed on the cell line. The tests do not apply to any particular lot.

Test Description	Test Provider	Test Method
Differentiation Potential by Teratoma	WiCell	SOP-CH-213 SOP-CH-214
HLA	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega
ABO	New York Blood Center	For ABO: Olsson ML, Chester MA. A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 1995; 69(3):242-7. For RHD: Singleton BK, Green CA, Avent ND, Martin PG, Smart E, Daka A, Narter-Olaga EG, Hawthorne LM, Daniels G. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000; 95(1): 12-8.
Growth Curve (Doubling Time)	WiCell	Varies by culture platform
Flow Cytometry for ESC Marker Expression	UW Flow Cytometry Laboratory	SOP-CH-101 SOP-CH-102 SOP-CH-103 SOP-CH-105
Comprehensive Human Virus Panel	Charles River	ID 91/0

Amendment(s):

Reason for Amendment	Date
CoA updated to include copyright information.	See Signature
CoA updated for format changes, including adding fields of thaw recommendation, vial label, protocol, and banked by. General Cell Line Testing CoA added to lot CoA.	26-JUL-2013
Original CoA	14-MAR-2012

Date of Lot Release	Quality Assurance Approval
14-March-2012	<p style="text-align: right;">1/3/2014</p> <p>X AMC _____</p> <p>AMC Quality Assurance Signed by: _____ ca</p>

Short Tandem Repeat Analysis*

Sample Report: 10255-STR

Label on Tube: 10255-STR

Sample Date: 10/14/11

Received Date: 10/14/11

Requestor: WiCell Research Institute

Test Date: 10/14/11

File Name: 111017_blb

Report Date: 10/19/11

Sample Name: (label on tube) 10255-STR**Description:** WiCell Research Institute
provided genomic DNA
221.4 ug/mL; 260/280 = 1.9

Locus	Repeat #	STR Genotype
D16S539	5, 8-15	12,13
D7S820	6-14	8,10
D13S317	7-15	12,12
D5S818	7-15	11,13
CSF1PO	6-15	11,11
TPOX	6-13	8,9
Amelogenin	NA	X,Y
TH01	5-11	9,9.3
vWA	11, 13-21	17,17

Comments: Based on the 10255-STR DNA dated and received on 10/14/11 from WiCell Research Institute, this sample (Label on Tube: 10255-STR) exactly matches the STR profile of the human stem cell line WA23 comprising 13 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human WA23 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 10255-STR DNA sample submitted corresponds to the WA23 stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.



10/20/11
Date

Molecular Diagnostics Laboratory



10/20/11
Date

Molecular Diagnostics Laboratory

* Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.


Test Facility:



This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.

Report Number
883878
Page 1 of 2

WiCell Research Institute



December 12, 2011
P.O. #:

STERILITY TEST REPORT

Sample Information:
1: WA07-CB-01 10297
2: WA14-WB0022 10298
3: WA13.C-CB-01 10299
4: WA23-WB0099 10300
5: WA23-WB0101 10301
6: WA23-WB0069 10302
7: Pt2K-CS011 10303

Date Received: November 17, 2011
Date in Test: November 22, 2011
Date Completed: December 06, 2011


Test Information: Test Codes: 30744, 30744A
Immersion, USP / 21 CFR 610.12
Procedure #: BS210WCR.201

TEST PARAMETERS	PRODUCT	
Number Tested	14	14
Type of Media	SCD	FTM
Media Volume	400 mL	400 mL
Incubation Period	14 Days	14 Days
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C
RESULTS	14 NEGATIVE	14 NEGATIVE

(continued)




Test Facility:



This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.

Report Number
883878
Page 2 of 2

WiCell Research Institute



December 12, 2011
P.O. #:

STERILITY TEST REPORT

PRODUCT	APPROXIMATE VOLUME TESTED (each media)
1	0.5 / 0.5 mL
2	0.3 / 0.45 mL
3	0.5 / 0.5 mL
4	0.5 / 0.5 mL
5	0.5 / 0.5 mL
6	0.4 / 0.4 mL
7	0.45 / 0.45 mL
8	0.5 / 0.5 mL
9	0.5 / 0.5 mL
10	0.4 / 0.4 mL
11	0.4 / 0.4 mL
12	0.4 / 0.4 mL
13	0.35 / 0.35 mL
14	0.5 / 0.5 mL

QA Reviewer

Date

12-13-11

Technical Reviewer

Date

12-12-11

Testing conducted in accordance with current Good Manufacturing Practices.





APPENDIX

Document ID #: DCF9002E
Title: QUALITY ASSURANCE REPORT - GMP
Effective Date: 03/24/10
Edition #: 03

QUALITY ASSURANCE REPORT - GMP

<u>TEST PERFORMED</u>	<u>PROCEDURAL REFERENCE</u>	<u>TEST PERFORMED</u>	<u>PROCEDURAL REFERENCE</u>
<input checked="" type="checkbox"/> M-250	SOP's 3008, 3011, 3013	<input type="checkbox"/> M-700	SOP's 3008, 3009, 3010
<input type="checkbox"/> M-300	SOP's 3008, 3014	<input type="checkbox"/> M-800	SOP's 3008, 3011, 3016
<input type="checkbox"/> M-350	SOP's 3008, 3014, 3015		

Bionique Sample ID #(s) 07215

This testing procedure was performed in compliance with the FDA's Current Good Manufacturing Practice (cGMP) standards (to the extent that the regulations pertain to the procedures performed) as specified in the Code of Federal Regulations, Title 21 Parts 210 and 211 [21 CFR 210 & 211]. All related records derived from the test procedures have been reviewed by the Quality Assurance Department. The individual's signature below verifies that the methods and procedures referenced above have been followed and that the Final Report accurately reflects the raw data generated during the course of the procedures. All records, including raw data and final reports are archived on site for a minimum of seven years.

The specified test's procedures determine the intervals at which samples are inspected. The medium used for testing must pass quality control mycoplasmal growth promotion testing and sterility testing. Traceability of all of the components used is assured and supporting documentation can be supplied upon request.

Quality Assurance Review Date: 11/17/11

Reviewed By QA Associate

NOTE:

1. Prior to receipt at Bionique® Testing Laboratories, Inc., the stability of the test article is the responsibility of the company submitting the sample. Bionique Testing Laboratories Inc. will assume responsibility for sample stability following receipt and prior to being placed on test.
2. This test is for the detection of microbiological growth and does not require statistical validation.

Document ID #: DCF9002E
Title: QUALITY ASSURANCE REPORT - GMP
Effective Date: 03/24/10
Edition #: 03

REFERENCES

Regulatory:

1. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. FDA. Office of the Federal Register, National Archives and Records Department.
2. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. FDA. Office of the Federal Register, National Archives and Records Department.
3. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals, Director, Center for Biologics Evaluation and Research, FDA. May, 1993. Docket No. 84N-0154.
4. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 610.30, General Biological Products Standards; Subpart D, Test for Mycoplasma. FDA. Office of the Federal Register, National Archives and Records Department.

General:

1. Barile MF, Kern J. Isolation of Mycoplasma arginini from commercial bovine sera and its implication in contaminated cell cultures. Proceedings of the Society for Experimental Biology and Medicine, Volume 138, Number 2, November 1971.
2. Chen, T.R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Experimental Cell Research, 104: 255-262, 1977.
3. Carolyn K. Lincoln and Daniel J. Lundin. Mycoplasma Detection and Control. U. S. Fed. for Culture Collections Newsletter, Vol. 20, Number 4, 1990.
4. Fetal Bovine Serum; Proposed Guideline. National Committee For Clinical Laboratory Standards (NCCLS), Vol. 10, Number 6, 1990. (NCCLS publication M25-P).
5. McGarrity GJ, Sarama J, Vanaman V. Cell Culture Techniques. ASM News, Vol. 51, No. 4, 1985.
6. Tully JG, Razin S. Methods in Mycoplasma, Volumes I and II. Academic Press, N.Y., 1983.
7. Barile MF, Razin S, Tully JG, Whitcomb RF. The Mycoplasmas, Volumes 1-4. Academic Press, N.Y., 1979.
8. <http://www.bionique.com/> - Safe Cells Insights

MYCOPLASMA TESTING SERVICES

APPENDIX IV

Page 1 of 2

Document#: DCF3013D
Edition#: 10
Effective Date: 07/15/2003
Title: **M-250 FINAL REPORT SHEET**

M-250 FINAL REPORT

Direct Specimen Culture
Procedure 3008, 3011, 3013

TO: **WiCell QA**
WiCell Research Institute

BTL SAMPLE ID#: **67215**

P.O.#: [REDACTED]

DATE REC'D: **10/20/2011**

TEST/CONTROL ARTICLE:

WA23-WB0101 #10255

LOT#: **NA**

DIRECT CULTURE SET-UP (DAY 0)

DATE: **10/20/2011**

INDICATOR CELL LINE (VERO)

SEE DNA FLUOROCHROME RECORD SHEET

DATE

THIOGLYCOLLATE BROTH	DAY 7	+	⊖	<u>10/27/2011</u>
	DAY 28	+	⊖	<u>11/17/2011</u>
BROTH-FORTIFIED COMMERCIAL				
<u>0.5</u> mL SAMPLE	DAY 7	+	⊖	<u>10/27/2011</u>
<u>6.0</u> mL BROTH	DAY 28	+	⊖	<u>11/17/2011</u>
BROTH-MODIFIED HAYFLICK				
<u>0.5</u> mL SAMPLE	DAY 7	+	⊖	<u>10/27/2011</u>
<u>6.0</u> mL BROTH	DAY 28	+	⊖	<u>11/17/2011</u>
BROTH-HEART INFUSION				
<u>0.5</u> mL SAMPLE	DAY 7	+	⊖	<u>10/27/2011</u>
<u>6.0</u> mL BROTH	DAY 28	+	⊖	<u>11/17/2011</u>

(See Reverse)

Document#: DCF3013D
 Edition#: 10
 Effective Date: 07/15/2003
 Title: M-250 FINAL REPORT SHEET



SAMPLE ID#:	67215	AEROBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+ ⊖	+ ⊖	<u>10/27/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/10/2011</u>
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+ ⊖	+ ⊖	<u>10/27/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/10/2011</u>
AGAR PLATES-HEART INFUSION	DAY 7	+ ⊖	+ ⊖	<u>10/27/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/10/2011</u>

BROTH SUBCULTURES (DAY 7)DATE: 10/27/2011

AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/10/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/17/2011</u>
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/10/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/17/2011</u>
AGAR PLATES-HEART INFUSION	DAY 7	+ ⊖	+ ⊖	<u>11/03/2011</u>
	DAY 14	+ ⊖	+ ⊖	<u>11/10/2011</u>
	DAY 21	+ ⊖	+ ⊖	<u>11/17/2011</u>

RESULTS: No detectable mycoplasmal contamination

11/17/11
 Date


 Laboratory Director /
 Ph.D.

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an *in vitro* cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both broth and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and microaerophilically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Issuance of the final report with signature of the Laboratory Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.



Document ID #: DCF3008A
Title: **DNA FLUOROCHROME ASSAY RESULTS**
Effective Date: 3/24/10
Edition #: 07

DNA-FLUOROCHROME ASSAY RESULTS

Procedures 3008, 3009, 3011

Sample ID # 67215 M-250 Date Rec'd: 10/20/2011 P.O. #

Indicator Cells Inoculated: Date/Initials: 10/20/11 | MLK

Fixation: Date/Initials: 10/24/11 | HS

Staining: Date/Initials: 10/24/11 | HS

TEST/CONTROL ARTICLE:

WA23-WB0101 #10255

LOT# NA

WiCell QA
WiCell Research Institute



Phone:

Fax #:

DNA FLUOROCHROME ASSAY RESULTS:

X **NEGATIVE:** A reaction with staining limited to the nuclear region, which indicates no mycoplasmal contamination.

 POSITIVE: A significant amount of extranuclear staining which strongly suggests mycoplasmal contamination.

 INCONCLUSIVE:

 A significant amount of extranuclear staining consistent with low - level mycoplasmal contamination or nuclear degeneration.

 A significant amount of extranuclear staining consistent with bacterial, fungal or other microbial contaminant or viral CPE. Morphology not consistent for mycoplasmal contamination.

COMMENTS:

Date: 10/24/11 Results Read by: HS Date of Review: 10/24/11 Reviewed by: SI

Report Date: October 07, 2011

Cell Line: WA23-WB0101 10255

Passage #: 20

Date of Sample: 10/3/2011

Date Completed: 10/7/2011


Results: 46,XY

Specimen: hESC on Matrigel

Cell Line Gender: Male

Reason for Testing: lot release testing

**Investigator: [REDACTED] WiCell
Derivation**



Cell: S02-24

Slide: 3(10)KARYOTYPE

Slide Type: Karyotyping

of Cells Counted: 40

of Cells Karyotyped: 4

of Cells Analyzed: 8

Band Level: 450-550

Interpretation:

No clonal abnormalities were detected at the stated band level of resolution.

Completed by [REDACTED], CG(ASCP), on 10/6/2011

Reviewed and interpreted by [REDACTED], PhD, FACMG, on 10/7/2011

A signed copy of this report is available upon request.

Date: _____

Sent By: _____

Sent To: _____

QC Review By: _____

Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the four karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e., mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

This assay was conducted solely for listed investigator/institution. The results may not be relied upon by any other party without the prior written consent of the Director of the WiCell Cytogenetics Laboratory. The results of this assay are for research use only. If the results of this assay are to be used for any other purpose, contact the Director of the WiCell Cytogenetics Laboratory.